Evidence & References
The references below are curated to support a mechanism-informed framework for Drug-Induced Mitochondrial Dysfunction (DIMD). Modern pharmacology and toxicology developed much of their safety architecture before mitochondrial biology fully matured as a clinical science. As a result, mitochondrial injury may not always fit neatly within traditional organ-specific toxicity models.
Organizing these studies by mechanism rather than by organ system highlights how DNA-interacting drugs, mitochondrial bioenergetics, and delayed tissue vulnerability intersect — and why certain adverse effects may appear progressive, multisystem, or temporally disconnected from initial exposure.
I. Foundational Mitochondrial Biology & Drug Toxicology
Wallace KB, Starkov AA. Mitochondrial targets of drug toxicity. Annu Rev Pharmacol Toxicol. 2000;40:353-388.
→ Classic review describing how diverse drugs impair mitochondrial respiration, increase oxidative stress, and disrupt cellular energy production.
Nadanaciva S, Will Y. Investigating mitochondrial dysfunction to increase drug safety in the pharmaceutical industry. Curr Drug Targets. 2011;12(6):774-786.
→ Establishes mitochondrial toxicity as a major, under-recognized mechanism of adverse drug effects.
Dykens JA, Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov Today. 2007;12(17-18):777-785.
→ Explains why mitochondrial injury may produce delayed, cumulative, and multisystem effects rather than acute organ failure.
Gray MW. Mitochondrial evolution. Science. 1999;283(5407):1476-1481.
→ Describes the bacterial ancestry of mitochondria, explaining why drugs targeting bacteria may affect mitochondrial systems.
II. Mechanisms: mtDNA Injury, Oxidative Stress & Energy Failure
Meyer JN, et al. Mitochondrial toxicity of environmental chemicals and pharmaceuticals. Toxicology. 2013;313(2-3):66-73.
→ Demonstrates how toxicants damage mitochondrial DNA and impair oxidative phosphorylation.
Scatena R. Mitochondria and drugs. Adv Exp Med Biol. 2012;942:329-346.
→ Reviews how commonly used medications disrupt mitochondrial metabolism and repair pathways.
Boelsterli UA, Lim PL. Mitochondrial abnormalities—a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol. 2007;220(1):92-107.
→ Highlights how mitochondrial dysfunction contributes to delayed and non-dose-dependent drug injury.
III. Fluoroquinolone-Specific Mechanisms
Reinhardt T, El Harraoui Y, Rothemann A, Jauch AT, Müller-Deubert S, Köllen MF, et al. Chemical proteomics reveals human off-targets of fluoroquinolone-induced mitochondrial toxicity. Angew Chem Int Ed. 2025;64(18):e202421424.
→ Identifies specific human mitochondrial protein targets of fluoroquinolones, demonstrating direct off-target interactions that impair respiratory chain function and cellular energy metabolism.
Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis. 2001;32(Suppl 1):S9-S15.
→ Describes bacterial DNA topoisomerase inhibition as the primary mechanism of action.
Lawrence JW, Claire DC, Weissig V, Rowe TC. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol. 1996;50(5):1178-1188.
→ Early evidence that ciprofloxacin induces mitochondrial DNA damage in mammalian cells.
Kalghatgi S, Spina CS, Costello JC, et al. Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells. Sci Transl Med. 2013;5(192):192ra85.
→ Demonstrates that bactericidal antibiotics can impair mammalian mitochondrial function and increase oxidative stress.
Kaufmann P, Török M, Zahno A, et al. Toxicity of fluoroquinolones: oxidative stress and mitochondrial damage. Toxicology. 2011;279(1-3):1-6.
→ Shows fluoroquinolones induce oxidative stress and mitochondrial impairment.
IV. Clinical Pattern: Delayed & Progressive Injury
Baxter R, Ray GT, Fireman BH. Case-control study of fluoroquinolone use and risk of Achilles tendon rupture. Am J Med. 2008;121(3):241-247.
→ Demonstrates association between fluoroquinolone exposure and delayed tendon rupture.
Pereira CV, et al. Drug-induced mitochondrial dysfunction and toxicity: from bench to bedside. Expert Opin Drug Metab Toxicol. 2009;5(5): 1-15.
→ Reviews how mitochondrial injury may present after exposure ends and progress over time.
V. Mechanistic Crosswalk: Topoisomerase Inhibition & Chemotherapy
Pommier Y. Topoisomerase I and II in cancer chemotherapy: update and perspectives. Nat Rev Cancer. 2010;10(10):690-702.
→ Authoritative review describing intentional topoisomerase inhibition as a chemotherapy strategy.